Literature DB >> 16641429

Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

John Quale1, Simona Bratu, Jyoti Gupta, David Landman.   

Abstract

Carbapenems are important agents for the therapy of infections due to multidrug-resistant Pseudomonas aeruginosa; the development of carbapenem resistance hampers effective therapeutic options. To assess the mechanisms leading to resistance, 33 clinical isolates with differing degrees of carbapenem susceptibility were analyzed for the expression of the chromosomal beta-lactamase (ampC), the porin that is important for the entry of carbapenems (oprD), and the proteins involved in four efflux systems (mexA, mexC, mexE, and mexX). Real-time reverse transcriptase PCR was performed using primers and fluorescent probes for each of the target genes. The sequencing of regulatory genes (ampR, mexR, nalC, nalD, mexT, and mexZ) was also performed. Diminished expression of oprD was present in all imipenem- and meropenem-resistant isolates but was not required for ertapenem resistance. Increased expression of ampC was not observed in several isolates that were overtly resistant to carbapenems. Increased expression of several efflux systems was observed in many of the carbapenem-resistant isolates. Increased efflux activity correlated with high-level ertapenem resistance and reduced susceptibility to meropenem and aztreonam. Most isolates with increased expression of mexA had mutations affecting nalC and/or nalD. Two isolates with mutations leading to a premature stop codon in mexZ had markedly elevated mexX expressions, although mutations in mexZ were not a prerequisite for overexpression. beta-Lactam resistance in clinical isolates of P. aeruginosa is a result of the interplay between diminished production of oprD, increased activity of ampC, and several efflux systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641429      PMCID: PMC1472219          DOI: 10.1128/AAC.50.5.1633-1641.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  Mutations affecting DNA-binding activity of the MexR repressor of mexR-mexA-mexB-oprM operon expression.

Authors:  Kohjiro Saito; Hiroyuki Akama; Eisaku Yoshihara; Taiji Nakae
Journal:  J Bacteriol       Date:  2003-10       Impact factor: 3.490

2.  Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates.

Authors:  Jean-Paul Pirnay; Daniel De Vos; Dimitris Mossialos; Alain Vanderkelen; Pierre Cornelis; Martin Zizi
Journal:  Environ Microbiol       Date:  2002-12       Impact factor: 5.491

3.  Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.

Authors:  Catherine Llanes; Didier Hocquet; Christelle Vogne; Dounia Benali-Baitich; Catherine Neuwirth; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Christelle Vogne; Julio Ramos Aires; Christiane Bailly; Didier Hocquet; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City.

Authors:  John Quale; Simona Bratu; David Landman; Renuka Heddurshetti
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

6.  Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates.

Authors:  Mara L Sobel; Geoffrey A McKay; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases.

Authors:  David L Paterson; Kristine M Hujer; Andrea M Hujer; Bethany Yeiser; Michael D Bonomo; Louis B Rice; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone.

Authors:  Didier Hocquet; Xavier Bertrand; Thilo Köhler; Daniel Talon; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

9.  In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM.

Authors:  I Ziha-Zarifi; C Llanes; T Köhler; J C Pechere; P Plesiat
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Enhancement of the mexAB-oprM efflux pump expression by a quorum-sensing autoinducer and its cancellation by a regulator, MexT, of the mexEF-oprN efflux pump operon in Pseudomonas aeruginosa.

Authors:  Hideaki Maseda; Isao Sawada; Kohjiro Saito; Hiroo Uchiyama; Taiji Nakae; Nobuhiko Nomura
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more
  126 in total

1.  blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program.

Authors:  H Aboufaycal; H S Sader; K Rolston; L M Deshpande; M Toleman; G Bodey; I Raad; R N Jones
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

2.  In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  Probing the binding affinities of imipenem and ertapenem for outer membrane carboxylate channel D1 (OccD1) from P. aeruginosa: simulation studies.

Authors:  Kamolrat Somboon; Jitti Niramitranon; Prapasiri Pongprayoon
Journal:  J Mol Model       Date:  2017-07-17       Impact factor: 1.810

Review 4.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

5.  Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City.

Authors:  Alejandro Iregui; Zeb Khan; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

6.  Full Resistance and decreased susceptibility to carbapenems in IMP-13-producing Pseudomonas aeruginosa isolates from an outbreak.

Authors:  Gisela Santella; Arabela Cuirolo; Marisa Almuzara; Susana Palombarani; Gabriela Sly; Marcela Radice; Gabriel Gutkind
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

Review 7.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 8.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

9.  Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Authors:  Bartolome Moya; Laura Zamorano; Carlos Juan; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.

Authors:  Keith S Kaye; Helen W Boucher; Michelle L Brown; Angela Aggrey; Ireen Khan; Hee-Koung Joeng; Robert W Tipping; Jiejun Du; Katherine Young; Joan R Butterton; Amanda Paschke
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.